FTO attenuates LPS-induced acute kidney injury by inhibiting autophagy via regulating SNHG14/miR-373-3p/ATG7 axis
International Immunopharmacology · 2024-02 · 128 · 111483
DOI: 10.1016/j.intimp.2023.111483 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-02. Verfasst von Ni Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, MicroRNAs, Acute Kidney Injury, Sepsis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Xi’an Jiaotong University, Key Research and Development Projects of Shaanxi Province.
Abstract (Originalsprache)
N6-methyladenosine (m6A) is a master driver of RNA function and implicates in the pathogenesis of renal injury. LncRNA SNHG14 is highly expressed in sepsis patients with acute kidney injury (AKI) and aggravates kidney cell dysfunction. This study aimed to explore whether demethylase FTO affect m6A methylation of SNHG14 in AKI injury and its underlying mechanism. The expression level of FTO was obviously downregulated in sepsis-associated AKI patients compared with normal controls. Mechanistically, FTO overexpression impeded SNHG14 expression by decreasing the stability of SNHG14 in an m6A-dependent manner in LPS-induced HK-2 cells. Additionally, FTO overexpression inhibited cell autophagy and apoptosis while promoting cell viability of LPS-induced HK-2 cells. Moreover, overexpression of FTO inhibited SNHG14 expression and autophagy in LPS-induced AKI mice. Functionally, SNHG14 acts as a competing endogenous RNA (ceRNA) via directly sponging miR-373-3p in LPS induced HK-2 cells. Additionally, miR-373-3p directly targets ATG7. Inhibition of SNHG14 suppresses NF-κB signaling pathway and production of inflammatory cytokines (TNF-α, IL-6, and IL-1β) via miR-373-3p/ATG7 in LPS-induced HK-2 cells. Furthermore, the SNHG14/miR-373-3p/ATG7 interaction network contributes to the regulatory effect of FTO on LPS-induced HK-2 cell viability, apoptosis and autophagy. These results suggested demethylase FTO suppressed the m6A modification of lncRNA SNHG14 and inhibits autophagy in LPS-induced AKI via regulating miR-373-3p/ATG7, which provided an important novel perspective for understanding sepsis-associated AKI and is conducive for developing new therapeutic targets and strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Cardio-cerebrovascular Hospital, Affiliated Hospital of Yan'an University, Yan'an, China.
- Department of Emergency, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: zhang_zlxa@163.com.
Förderung
- National Institutes of Health
- Xi’an Jiaotong University
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Yang, N., Yan, N., Bai, Z., Du, S., Zhang, J., Zhang, L., & Zhang, Z. (2024). FTO attenuates LPS-induced acute kidney injury by inhibiting autophagy via regulating SNHG14/miR-373-3p/ATG7 axis. International Immunopharmacology, 128, 111483. https://doi.org/10.1016/j.intimp.2023.111483
Vancouver
Yang N, Yan N, Bai Z, Du S, Zhang J, Zhang L, et al. FTO attenuates LPS-induced acute kidney injury by inhibiting autophagy via regulating SNHG14/miR-373-3p/ATG7 axis. International Immunopharmacology. 2024;128:111483. doi:10.1016/j.intimp.2023.111483
BibTeX
@article{Yang2024,
author = {Yang, Ni and Yan, Na and Bai, Zhenghai and Du, Shuang and Zhang, Jingjing and Zhang, Li and Zhang, Zhengliang},
title = {FTO attenuates LPS-induced acute kidney injury by inhibiting autophagy via regulating SNHG14/miR-373-3p/ATG7 axis},
journal = {International Immunopharmacology},
year = {2024},
volume = {128},
pages = {111483},
doi = {10.1016/j.intimp.2023.111483}
}
EUVIMED